| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
McKesson joins leading distribution service providers as authorized U.S. distributor of LYMPHIR
CRANFORD, N.J., Oct. 20, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced it has entered into a distribution services agreement with McKesson Corporation (NYSE:MCK), one of the largest pharmaceutical distributors and healthcare services companies in North America. Under the agreement, McKesson will serve as an authorized distributor of record for LYMPHIR (denileukin diftitox-cxdl), a novel immunotherapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
The agreement with McKesson completes Citius Oncology's core U.S. distribution network for LYMPHIR, which now includes all three of the largest pharmaceutical distributors in the country. This strategic milestone ensures broad and reliable access to the therapy in preparation for its planned commercial launch in the fourth quarter of 2025.
